Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Clinical characteristics and treatment outcome of COVID-19 patients with stroke in China: A multicenter retrospective study

Xin-yu Ji a,1, Yan Ma a,1, Nan-nan Shi a,1, Ning Liang a, Ren-bo Chen a, Si-hong Liu b, Shuai Shi c, Gui-hui Wu d, Ji-ke Li c, Hong Chen c, Jing-wei Wang e, Hui Na g, Ying-chun Zhou h, Min-qing Li f, Yu-dong Wang j, Xiao-mei Hu k, Yun-hong Hu i, Zhang Liu m, Hai-jun Xie n, Lin-song Zhang o, Hua-min Zhang p,q,r, Yan-ping Wang a,s, Yong-yan Wang a,s

a Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
b Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China
c Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
d Department of tuberculosis, The Public Health Clinical Center of Chengdu, Sichuan, China
e Department of traditional Chinese medicine, The Public Health Clinical Center of Chengdu, Sichuan, China
f Department of infectious disease, Harbin Infectious Disease Hospital, Heilongjiang, China
g Department of infectious disease, Shuangyang People’s Hospital, Heilongjiang, China
h Department of traditional Chinese medicine, Daizhou Central Hospital, Sichuan, China
i Hengshui Hospital of Chinese Medicine, Hebei, China
j Department of traditional Chinese medicine, Langfang Hospital of Chinese Medicine, Hebei, China
k Department of traditional Chinese medicine, Xingtai Hospital of Chinese Medicine, Hebei, China
l Department of traditional Chinese medicine, The First Hospital of Sichuan City, Chengdu, Sichuan, China
m Department of infectious disease, Shuangyang People’s Hospital, Shandong, China
n Department of Chinese materia medica, Hospital (T&CM) Affiliated to Southwest Medical University, Sichuan, China
o Institute of Basic Research in Clinical Medicine and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China

A R T I C L E   I N F O

Keywords:
COVID-19
Clinical characteristics
Stroke
Treatment outcome

A B S T R A C T

Objective: Previous studies mainly reported the clinical characteristics of novel coronavirus 2019 (COVID-19) infections, but the research on clinical characteristics and treatment outcomes of COVID-19 patients with stroke is still rare.

Methods: A multi-center retrospective study was conducted at 11 hospitals in 4 provinces of China, and COVID-19 patients with stroke were enrolled from February 24 to May 4, 2020. We analyzed epidemiological, demographic, and clinical characteristics of cases as well as the laboratory test results, treatment regimens and outcomes, and the clinical characteristics and therapeutic outcomes were compared between severe and non-severe patients, and by age group, respectively.

Results: A total of 27 patients [mean age: 66.41 (SD 12.1) years] were enrolled. Among them, 9 (33.3%) were severe patients and 18 (66.7%) were nonsevere patients; 17 (63.0%) were female; 19 (70.4%) were aged 60 years and above. The most common symptoms were fever [19 (70.4%)], fatigue [12 (44.4%)] and cough [11 (40.7%)], respectively. Abnormal laboratory findings of COVID-19 patients with stroke included high levels of C-reactive protein [19 (73.1%)], D-dimer [14 (58.3%)], blood glucose [14 (53.8%)], fibrinogen [13 (50.0%)], and decreased lymphocytes [12 (44.4%)]. Comparing to nonsevere cases with stroke, severe patients with stroke were likely to be older, susceptible to receiving oxygen inhalation, and had more complications (p < 0.05). In addition, there were significant differences in lymphocytes, neutrophils, lactate dehydrogenase, C-reactive protein, creatine kinase between the severe cases and nonsevere cases (p < 0.05). The older patients had a

Abbreviations: COVID-19, novel coronavirus disease 2019; CT, computed tomography; ICU, intensive care unit; LDH, lactate dehydrogenase; PaO2, arterial partial pressure of oxygen; SARS-CoV, severe acute respiratory syndrome coronavirus; TIA, transient ischemic attack.

* Corresponding author: Institute of Basic Research in Clinical Medicine and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No.16 Dongzhimen Nei Nan Xiao Jie, Dongcheng District, 100700, Beijing, China.
E-mail addresses: zhanghun@mail.cintcm.ac.cn (H.-m. Zhang), wangyyping4816@163.com (Y.-p. Wang), wangyongyan1938@126.com (Y.-y. Wang).

These authors contributed equally to this article.

https://doi.org/10.1016/j.phymed.2020.153433

Received 3 September 2020; Received in revised form 25 October 2020; Accepted 2 December 2020

Available online 4 December 2020

0944-7113/© 2020 Elsevier GmbH. All rights reserved.
Introduction

The novel coronavirus disease 2019 (COVID-19) has posed a significant global health threat (Huang et al., 2020, Phelan et al., 2020, Zhu et al., 2020). As of 22 October 2020, there have been over 40 million confirmed COVID-19 cases and more than 1 million deaths reported across the world (World Health Organization WHO, 2020). The most prominent symptoms of COVID-19 are fever, cough, and fatigue (Chen et al., 2020; Huang et al., 2020). The neurologic manifestations of COVID-19 infections have also received increasing attention, including acute cerebrovascular diseases, and impaired consciousness (Mao et al., 2020a).

A previous retrospective study demonstrated that there were 30 (1.9%) patients suffering cerebrovascular diseases among all hospitalized COVID-19 patients (Guan et al., 2020b), and another study from China also found that 5.7% severe infections among 214 hospitalized COVID-19 patients had suffered stroke (Mao et al., 2020b). Furthermore, a higher incidence of thromboembolic complications including stroke were also found in the severe acute respiratory syndrome (SARS) infections in 2003 (Umapathi et al., 2004). One of the emerging clinical characteristics of severe SARS-CoV-2 infections was coagulopathy with high levels of D-dimer and fibrinogen (Tang et al., 2020). Thrombosis is a key mechanism for many acute ischemic strokes, and a higher basal plasma D-dimer concentration is a risk marker for ischemic stroke (Folsom et al., 2016) in the general population. Studies revealed that hypercoagulability associated with COVID-19 were more likely to have stroke (Hess et al., 2020, Connors and Levy, 2020). According to autopsy findings of COVID-19 patients, the high incidence of thromboembolic events suggests an important role of COVID-19-induced coagulopathy (Wichmann et al., 2020). In addition, previous literature revealed that COVID-19 patients with aged 50 years presented with symptoms of large-vessel ischemic stroke within 2 weeks after illness onset, with a risk much higher than other times (Oxley et al., 2020). Some experts also explored the potential influence of racial background in stroke outcomes in this pandemic (Dmytriw et al., 2020). Therefore, the stroke with COVID-19 or potentially caused by SARS-CoV-2 infections has attracted more and more attention (Avula et al., 2020; Beyrouti et al., 2020; Markus and Brainin, 2020).

However, our current understanding of COVID-19 patients with stroke history or acute stroke remains limited. Especially, so far, there are few studies that have systematically compared clinical characteristics, laboratory and radiologic findings, and treatment outcome of COVID-19 patients with stroke by severity and age group. Therefore, we performed a retrospective study to investigate the clinical characteristics and therapeutic outcomes of COVID-19 patients with stroke, with the comparison between severe and nonsevere infections, and patients aged < 60 years and aged ≥ 60 years. The findings of our study can provide useful information for designing novel strategy for stroke patient treatment under the ongoing and future waves of COVID-19 pandemic.

METHODS

Study population

The multicenter retrospective study was conducted at 11 hospitals in 4 provinces of China from February 24 to May 4, 2020. All stroke patients with laboratory confirmed COVID-19 were enrolled. The diagnosis of COVID-19 was based on guidelines issued by the National Health Commission of the People’s Republic of China (China., 2020.). This study was approved by the National Administration of Traditional Chinese Medicine, the Administration of Traditional Chinese Medicine in 4 provinces and the institutional board of 11 participating hospitals. Based on the urgent need to collect data and treat COVID-19 patients, the written informed consent was replaced by verbal consent.

Definition

Fever was defined as axillary temperature of at least 37.3 °C. The diagnosis of stroke was made by clinicians according to the health history of patients and images of brain chest computed tomography (CT) on admission. The severity of the disease was categorized by using the guidelines for diagnosis and treatment of COVID-19 (seventh edition) issued by the National Health Commission of China (China., 2020.). Definitions of the severity for SARS-CoV-2 infections are described as follows. 1) Mild cases: The clinical symptoms were mild, and there was no sign of pneumonia on imaging; 2) Moderate cases: Showing fever and respiratory symptoms with radiologic findings of pneumonia; 3) Severe cases: (i) Respiratory distress (≥ 30 breaths/min); (ii) Oxygen saturation ≤ 93% at rest; (iii) Arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤ 300mmHg (1 mmHg = 0.133kPa). In high-altitude areas (at an altitude of over 1,000 meters above the sea level), PaO2/FiO2 should be corrected by the following formula: PaO2/FiO2 [Atmospheric pressure (mmHg)/760]. Cases with the chest imaging that shows obvious lesion progression within 24 - 48 hours >50% should be managed as severe cases. Nonsevere patients included mild and moderate cases.

Data collection

Epidemiological, demographic, clinical, laboratorial, radiological, and treatment data were collected and obtained from patients’ electronic medical records provided by each hospital. Two researchers independently checked the eligibility of patients for this study and extracted data. Data were entered into a database and cross-checked. If the core data such as clinical characteristics, laboratory and radiologic findings, treatment outcome were unclear or missing, we would send requests for clarification to the coordinator for this project in each hospital, who subsequently contacted the clinicians involved in this study.

Statistical Analysis

Continuous variables were described using mean with standard deviation (SD) and median with interquartile range (IQR), as appropriate. Categorical data were presented as counts and percentages. Continuous variables were compared by t tests if the data were assumed with a normal distribution; otherwise, by using the Mann-Whitney test. Proportions for categorical variables were compared using the χ² test or Fisher exact test between severe and non-severe groups, patients aged < 60 years and aged ≥ 60 years. Statistical analysis was performed with R.
Characteristics of patients by clinical severity and age group.

Table 1  

| Characteristic                        | Total (N = 27) | Clinical severity | Age group | p   | p   |
|--------------------------------------|---------------|------------------|-----------|-----|-----|
|                                      |               | Nonsevere (N = 18) | Severe (N = 9) | ≥ 60 years (N = 19) | < 60 years (N = 8) |   |
| Age, mean (SD), yr                   | 66.4 ± 12.1  | 62.4 ± 12.0       | 74.3 ± 8.0  | 0.006 | 72.5 ± 8.3 | 51.9 ± 5.4 | <0.001 |
| Age (categorized)                    |               |                  |            |      |      |      |     |
| ≤ 60 yr - no./total no. (%)          | 19 (70.4)    | 10 (55.6)         | 9 (100)    | 0.026 | -    | -    | -    |
| < 60 yr - no./total no. (%)          | 8 (29.6)     | 8 (44.4)          | 0 (0)      | -    | -    | -    | -    |
| Sex - no. (%)                        |               |                  |            |      |      |      |     |
| Male                                 | 17 (63.0)    | 11 (61.1)         | 6 (66.7)   | 1.000 | 12 (63.2) | 5 (62.5) | 1.000 |
| Female                               | 10 (37.0)    | 7 (38.9)          | 3 (33.3)   | 1.000 | 3 (15.8)  | 3 (37.5) | 1.000 |
| Smoking history - no./total no. (%)  | 8 (29.6)     | 6 (33.3)          | 2 (22.2)   | 0.676 | 7 (36.8)  | 1 (12.5) | 0.364 |
| Drinking history - no./total no. (%) | 9 (33.3)     | 7 (38.9)          | 2 (22.2)   | 0.667 | 6 (31.6)  | 3 (37.5) | 1.000 |
| Profession - no./total no. (%)       |               |                  |            |      |      |      |     |
| Farmers                              | 8 (29.6)     | 8 (44.4)          | 0 (0)      | 0.034 | 5 (26.3)  | 3 (37.5) | 0.304 |
| Non-salary employee                  | 13 (48.2)    | 6 (33.3)          | 7 (77.8)   | 1.000 | 11 (57.9) | 2 (25)   | 1.000 |
| Salary employee                      | 6 (22.2)     | 4 (22.2)          | 2 (22.2)   | 1.000 | 3 (15.8)  | 3 (37.5) | 1.000 |
| History of travel and contact - no. (%) |           |                  |            |      |      |      |     |
| Exposure to source of transmission within past 14 days | 7 (25.9) | 5 (27.8) | 2 (22.2) | 1.000 | 5 (26.3) | 2 (25) | 1.000 |
| Contact with COVID-19 patients       | 15 (55.6)    | 10 (55.6)         | 5 (55.6)   | 1.000 | 11 (57.9) | 4 (50)   | 1.000 |
| Coexisting disorder -no./total no. (%) |           |                  |            |      |      |      |     |
| Any                                  | 17 (63.0)    | 8 (44.4)          | 9 (100)    | 0.009 | 13 (68.4) | 4 (50)   | 0.415 |
| Hypertension                         | 13 (48.2)    | 5 (27.8)          | 8 (88.9)   | 0.004 | 10 (52.6) | 3 (37.5) | 0.678 |
| Diabetes                             | 7 (25.9)     | 5 (27.8)          | 2 (22.2)   | 1.000 | 5 (26.3)  | 2 (25)   | 1.000 |
| Cardiovascular disease               | 2 (7.4)      | 0 (0)             | 2 (22.2)   | 0.103 | 2 (10.5)  | 0 (0)    | 1.000 |
| Symptoms - no. (%)                   |               |                  |            |      |      |      |     |
| Body temperature, mean (SD), °C      | 37.5 ±0.7    | 37.6 ±0.8         | 37.4 ±0.4  | 0.655 | 37.4 ±0.6 | 37.7 ±0.8 | 0.256 |
| Fever                                | 19 (70.4)    | 13 (72.2)         | 6 (66.7)   | 1.000 | 13 (68.4) | 6 (75)   | 1.000 |
| Fatigue                              | 12 (44.4)    | 9 (50)            | 3 (33.3)   | 0.683 | 9 (47.4)  | 3 (37.5) | 0.696 |
| Cough                                | 11 (40.7)    | 7 (38.9)          | 4 (44.4)   | 1.000 | 9 (47.4)  | 2 (25)   | 0.405 |
| Dyspnoea or tachypnoea               | 5 (18.5)     | 4 (22.2)          | 1 (11.1)   | 0.636 | 4 (21.1)  | 1 (12.5) | 1.000 |
| Sore throat                          | 2 (7.4)      | 2 (11.1)          | 0 (0)      | 0.538 | 0 (0)    | 2 (25)   | 0.080 |
| Diarrhea                             | 2 (7.4)      | 0 (0)             | 2 (22.2)   | 0.103 | 2 (10.5)  | 0 (0)    | 1.000 |
| Complications - no. (%)              |               |                  |            |      |      |      |     |
| Any                                  | 8 (29.6)     | 2 (11.1)          | 6 (66.7)   | 0.006 | 8 (42.1)  | 0 (0)    | 0.040 |
| Onset of symptom to hospital admission, median (IQR), d | 3 (1, 7.5) | 2 (3.5) | 2 (6.5) | 0.897 | 3 (0.5, 7) | 4.5 (2, 10.3) | 0.251 |
| Hospital admission, median (IQR), d   | 16 (14, 22.50) | 16 (13.3, 20.8) | 19.5 (14.8, 26.8) | 0.387 | 20 (15, 25.5) | 13.5 (11, 15.5) | 0.015 |
| Days of first viral shedding, mean (SD), d | 13.9 ±6.4 | 12.2 ±5.5 | 17.9 ±7.8 | 0.087 | 15.1 ±6.7 | 11.4 ±4.4 | 0.120 |
| Treatment - no. (%)                  |               |                  |            |      |      |      |     |
| Oxygen inhalation                    | 18 (66.7)    | 9 (50)            | 9 (100)    | 0.012 | 14 (73.7) | 4 (50)   | 0.375 |
| Antiviral drugs                      | 27 (100)     | 19 (100)          | 8 (100)    | 1.000 | 19 (100)  | 8 (100)  | 1.000 |
| Antibiotics                          | 12 (44.4)    | 8 (44.4)          | 4 (44.4)   | 1.000 | 1 (5.3)   | 2 (25)   | 0.201 |
| Traditional Chinese medicine         | 26 (96.3)    | 18 (100)          | 8 (88.9)   | 0.333 | 18 (94.7) | 8 (100)  | 1.000 |

Data are median (IQR), mean (SD), n (%), or n/N (%), where N is the total number of patients with available data.
P values indicate differences between clinical severity and age group. p < 0.05 was considered statistically significant.
COVID-19 = coronavirus disease 2019.
According to a report in 2014, China reported the largest number of cases of stroke in the world (Feigin et al., 2014). COVID-19 patients with stroke had more severe clinical symptoms and poorer outcomes compared to patients without stroke (Qin et al., 2020). Thus, it is of importance to understand clinical feature, laboratory findings, and treatment outcome of COVID-19 patients with stroke by clinical severity and age group.

In our study, we found that severe cases had high levels of neutrophils count and C-reactive protein. Additionally, the increasing levels of lactate dehydrogenase (LDH) and creatine kinase were also observed in severe patients. The LDH was an inflammatory predictor in many pulmonary diseases (Inamura et al., 2014) and significantly higher in respiratory COVID-19 pneumonia (Mo et al., 2020). These findings suggest that a cytokine storm and infections might be associated with the severity of COVID-19.

In laboratory tests, C-reactive protein was elevated in two-thirds of COVID-19 patients with stroke and creatinine kinase was increased in more than half of them. Therefore, patients with COVID-19 and stroke should pay attention to pre-clotting state. A recent study showed that the deceased cases had significantly higher D-dimer and fibrin degradation product (FDP) levels, which might indicate the presence of an abnormal clot (Tang et al., 2020b). These include hypercoagulability as evidenced by increased levels of D-dimer, fibrinogen, and fibrin degradation products (FDP) in COVID-19 patients with stroke (Markus et al., 2020; Breakey and Escher, 2020, Qin et al., 2020). On admission, COVID-19 patients with low activated partial thromboplastin time and elevated fibrinogen in therapy demonstrated that patients with stroke should pay attention to pre-clotting state. A recent study showed that the deceased cases had significantly higher D-dimer and fibrin degradation product (FDP) levels, which might indicate the presence of an abnormal clot (Tang et al., 2020b). These include hypercoagulability as evidenced by increased D-dimer levels (Tang et al., 2020a). The indicator of D-dimer higher than 1 μg/ml might help physicians to identify patients with poor prognosis at the early stage of infections (Zhou et al., 2020a).

In addition, the elderly were more susceptible to suffer severe illness and 19 (70.4%) were aged ≥ 60 years. The older patients had a decrease of platelet counts (p = 0.025) and an increase of fibrinogen (p = 0.013), compared to the younger patients.

### Treatment regimens and outcomes

In our study, all patients received antiviral treatment, 12 (44.4%) received antibiotics treatment, 26 (96.3%) received Traditional Chinese Medicine (Lung cleansing & detoxifying decoction), and 18 (66.7%) received oxygen inhalation. The median duration of hospitalization was 16 days. Compared with nonsevere patients, severe patients had more complications such as atherosclerotic plaque initiation [4 (44.4%)] respiratory failure [3 (33.3%)], shock [1 (11.1%)], myocardial injury [1 (11.1%)], and ARDS [1 (11.1%)]. As of May 4, 2020, a total of 26 patients were cured and discharged, and 1 case died.

The Fig 2. has detailed the epidemiological history and treatment outcomes of these 27 patients. Among all patients, 4 cases (14.8%) were referred from the sites for quarantine and medical observation or other hospitals to the hospitals participated in this study. In addition, patients (no. 6 and 9) had developed acute stroke after admission to hospital; and the acute stroke of patients (no. 3, 4 and 5) occurred within 1 month before COVID-19 onset, while two of them (no. 4 and 5) developed a transient ischemic attack (TIA) during hospitalization after illness onset.

### DISCUSSION

The COVID-19 has posed major public health threats affecting billions of people worldwide with considerable impacts on stroke (Markus and Brainin, 2020). According to a report in 2014, China reported the largest number of cases of stroke in the world (Feigin et al., 2014). COVID-19 patients with stroke had more severe clinical symptoms and poorer outcomes compared to patients without stroke (Qin et al., 2020). Thus, it is of importance to understand clinical feature, laboratory findings, and treatment outcome of COVID-19 patients with stroke by clinical severity and age group.

In our study, we found that severe cases had high levels of neutrophils count and C-reactive protein. Additionally, the increasing levels of lactate dehydrogenase (LDH) and creatine kinase were also observed in severe patients. The LDH was an inflammatory predictor in many pulmonary diseases (Inamura et al., 2014) and significantly higher in respiratory COVID-19 pneumonia (Mo et al., 2020). These findings suggest that a cytokine storm and infections might be associated with the severity of COVID-19.

In laboratory tests, C-reactive protein was elevated in two-thirds of COVID-19 patients with stroke and creatinine kinase was increased in more than half of them. Therefore, patients with COVID-19 and stroke should pay attention to pre-clotting state. A recent study showed that the deceased cases had significantly higher D-dimer and fibrin degradation product (FDP) levels, which might indicate the presence of an abnormal clot (Tang et al., 2020b). These include hypercoagulability as evidenced by increased D-dimer levels (Tang et al., 2020a). The indicator of D-dimer higher than 1 μg/ml might help physicians to identify patients with poor prognosis at the early stage of infections (Zhou et al., 2020a).

In addition, the elderly were more susceptible to suffer severe illness
Table 3

Laboratory and radiologic findings between aged ≥60 years and aged <60 years among COVID-19 patients with stroke.

| Laboratory and radiologic findings | Aged ≥ 60 years (N = 19) | Aged < 60 years (N = 8) | p   |
|-----------------------------------|--------------------------|-------------------------|-----|
| Laboratory tests (reference values) |                          |                          |     |
| White blood cells (4-10 × 10⁹ cells per l) | 6.2 ± 2.0                | 6.1 ± 2.0                | 0.904 |
| Increased (n/N; %)       | 2/19 (10.5)               | 1/8 (12.5)               |     |
| Lymphocytes (1.1-3.2 × 10⁹ cells per l) | 1 ± 0.5                  | 1 ± 0.8                  | 0.312 |
| Decreased (n/N; %)       | 8/19 (42.1)               | 4/8 (50)                 |     |
| Neutrophils count (1.8-6.3 × 10⁹ cells per l) | 4.8 ± 2                  | 4.3 ± 1.6                | 0.542 |
| Increased (n/N; %)       | 4/19 (21.1)               | 1/8 (12.5)               |     |
| Platelet count (< 10⁹ per l; normal range 125.0-350.0) | 179.4 ± 60.2             | 231.4 ± 45.7             | 0.025 |
| Decreased (n/N; %)       | 2/19 (10.5)               | 0/8 (0)                  |     |
| Lactate dehydrogenase (U/l; normal range 20.0-250.0) | 256.9 ± 66               | 206.6 ± 54.8             | 0.060 |
| Increased (n/N; %)       | 8/18 (44.4)               | 2/8 (25)                 |     |
| C-reactive protein (mg/l; normal range 0.0-5.0) | 24.1 (12, 49)            | 5.4 (4.9, 12.6)          | 0.085 |
| Increased (n/N; %)       | 15/18 (83.3)              | 4/8 (50)                 |     |
| Prothrombin time (s; normal range 10.5-13.5) | 12.6 ± 13.5              | 11.5 ± 10.5              | 0.140 |
| Increased (n/N; %)       | 4/19 (21.1)               | 0/7 (0)                  |     |
| Fibrinogen (g/l; normal range 2.0-4.0) | 4.1 ± 1                  | 2.8 ± 0.8                | 0.013 |
| Increased (n/N; %)       | 11/19 (57.9)              | 1/7 (14.3)               |     |
| D-dimer (μg/l; normal range 0.0-5.0) | 0.7 (0.4, 1.2)           | 0.7 (0.2, 1.6)           | 0.689 |
| Increased (n/N; %)       | 10/18 (55.6)              | 3/6 (50)                 |     |
| CT findings - no./total no. (%) |                          |                          |     |
| Bilateral pulmonary opacities | 17/19 (89.5)             | 6/8 (75)                 | 0.448 |
| Unilateral pulmonary opacities | 1/19 (5.3)               | 2/8 (25)                 |     |

Note: Data are presented with median (IQR), mean (SD), n (%), or n/N (%). Where N is the total number of patients with available data. P values indicate differences between different age groups (<60 years vs. older than 60 years), and p < 0.05 was considered as statistically significance.

- Increased means over the upper limit of the normal range.
- Decreased means below the lower limit of the normal range.

and be admitted to the intensive care unit (ICU), and the mortality of patients aged ≥60 years were higher (Liu et al., 2020, Guan et al., 2020b, Pan et al., 2020). Our data demonstrated that lower platelet counts and higher levels of fibrinogen were observed in old persons of over 60 years. According to a primary prevention trial, among Chinese hypertensive adults, low platelet counts had a highest risk of first stroke (Kong et al., 2018). Severe thrombocytopenia likely contributed to the cerebral hemorrhage (Dixon et al., 2020). Moreover, fibrinogen is an essential hemostatic factor and primary phase inflammation marker, which is primarily involved in platelet–platelet interactions in thrombus formation (Davalos and Akassoglou, 2012, Petersen et al., 2018). These results suggest that the antithrombotic medication might be adjusted for COVID-19 patients with stroke according to the platelet counts or coagulation function.

Among 27 patients, severe cases have more complications, two patients had developed acute stroke, and three patients with acute stroke had received systemic treatment within one month before COVID-19 admission. Subsequently, the three patients then presented to the hospital again while they had a close contact with COVID-19 patient, and two patients developed TIA on admission. The early initiation of existing treatments after TIA or minor stroke was associated with an 80% reduction of the risk of early recurrent stroke (Rothwell et al., 2007). However, the underlying mechanisms remain unknown. Studies demonstrated that most coronaviruses are neurotropic, and others speculated that SARS-CoV-2 has same features (Steardo et al., 2020). The SARS-CoV-2 uses the same cell entry receptor-angiotensin-converting enzyme II (ACE2) as SARS-CoV (Zhou et al., 2020b). The ACE2 is present in the brain stem (Steardo et al., 2020), potentially allowing SARS-CoV-2 to cross the blood-brain barrier and affect the central nervous system (Chen et al., 2014). The experimental animal studies for SARS-CoV have shown that virus particles could be detected in specific brain areas (Hu et al., 2018; Li et al., 2016). In this case, an underlying inflammatory and hypercoagulable state might incite cerebrovascular disease without the disruption of blood–brain barrier (Al Saiegh et al., 2020).

In the present study we also found that, similar to patients with aged ≥60 years, severe COVID-19 patients had more comorbidities, poorer laboratory and radiologic findings, longer days of first viral shedding...
and hospital admission, compared to the non-severe cases. However, the overall treatment outcome was favorable with a cure rate of 96.3% (26/27).

There were several limitations in our study. First, although our study were conducted at 11 hospitals in 4 provinces, the small sample size of 27 patients might cause a high biases or uncertainty on the conclusions regarding factors associated with clinical outcome. Thus, further multicenter and long-term studies with a bigger sample size might be needed to draw a clear and robust conclusion. Second, given the need to treat patients at urgent timeline and outbreak response, some of clinical laboratory tests and data were not available for each patient. Despite these limitations, there are some notable strengths. We found that COVID-19 patients with stroke had both elevated C-reactive protein and D-dimer. Severe patients had increased inflammatory state, and older patients had an upregulation of fibrinogen and D-dimer. We also revealed that complications such as vascular embolism occurred more frequently in severe patients, and the coagulation system of elderly stroke patients was worse, which might lead to poor prognosis. This study improves our understanding on the clinical feature, laboratory and radiologic findings, and treatment outcome of COVID-19 patients with stroke, which can provide important evidence for clinicians to optimize treatment regimens and improve favorable outcome during the ongoing and future waves of COVID-19 pandemic.

Author contributions

Y.Y.W., Y.P.W., H.M.Z., Y.M., and X.Y.J. designed the study. X.Y.J. and Y.M. carried out the statistical analysis, drew the tables and pictures. X.Y.J., Y.M., and N.N.S. wrote the manuscript. N.L., R.B.C., S.H.L., and S.S. conducted data extraction and helped to draft the manuscript. G.H.W., H.C., J.W.W., H.N., Y.C.Z., M.Q.L., Y.D.W., X.M.H., Y.H.H., Z.L., H.J.X., and L.S.Z. recruited patients. Y.Y.W., Y.P.W., H.M.Z., Y.M., N.N.S., and X.Y.J. revised the final paper. All data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.

Declaration of Competing Interest

The authors declare that they have no competing interests.

Acknowledgments

We would like to thank all participants in the study, and we thank Prof Shenjie Lai for language editing of the manuscript. This study was supported by the National Science and Technology Major Project of China (2018ZX10101001-005-003, 2018ZX10101001-005-004). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Reference

Al Saiegh, F., Ghosh, R., Leibold, A., Avery, M.B., Schmidt, R.F., Theofanis, T., Mouchtouri, N., Philipp, L., Peiper, S.C., Wang, Z.X., Rincon, F., Tjoijmakaris, S.I., Jabbour, P., Roewerwaner, R.H., Groch, M.R., 2020. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. Journal of neurology, neurosurgery, and psychiatry.

Avula, A., Nalleballe, K., Narula, N., Sapozhnikov, S., Danhu, V., Toom, S., Glaser, A., Elsayegh, D., 2020. COVID-19 presenting as stroke. Brain, behavior, and immunity.

Beyrouti, R., Adams, M.E., Benjamin, L., Cohen, H., Farmer, S.F., Goh, Y.Y., Humphries, F., Jager, H.R., Loseff, N.A., Perry, R.J., Shah, S., Simister, R.J., Turner, D., Chandrathavea, A., Werring, D.J., 2020. Characteristics of ischaemic stroke associated with COVID-19. Journal of neurology, neurosurgery, and psychiatry.

Breakey, N., Escher, R., 2020. D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue? Swiss medical weekly 150, w20293.

Chen, J., Zhao, Y., Chen, S., Wang, J., Xiao, X., Ma, X., Penchikala, M., Xia, H., Lazartigues, E., Zhao, B., Chen, Y., 2014. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Neuropharmacology 79, 550–558.

Chen, N., Zou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., Zhang, L., 2020. Epidemiological and clinical
Liu, K., Chen, Y., Lin, R., Han, K., 2020. Clinical features of COVID-19 in elderly patients: a retrospective cohort study. Blood 135, 2033–2040.

Davalos, D., Aksagolou, K., 2012. Fibronogen as a key regulator of inflammatory disease. Seminars in immunopathology 34, 43–62.

Dixon, I., Varley, J., Gontsava, A., Malinos, D., Fona, T., Mair, D., Lugmani, A., Jenkins, I.H., Nicholas, J., Bros, E., 2020. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anaemia. Neurology(uk) neuroimmunology & neuroinflammation 7.

Dmytryeu, A.A., Pan, K., Schirmer, C., Settecase, F., Heran, M.K.S., Efenziade, A., Kühn, A.L., Puri, A.S., Menon, B.K., Dibar, M., Sivakumar, S., Mowla, A., Leung, L.Y., Malek, A.M., Voetsch, B., Sehgal, S., Waehlko, A.K., Wu, H., Xavier, A., Tiwar, A., 2020. Invasive aspergillus associated with COVID-19 and racial outcome disparity in North America. Journal of neurology, neurosurgery, and psychiatry.

Feigin, V.L., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensah, G.A., Connor, M., Bennett, D.A., Forouranzar, M.H., Krishnaswathi, R., Mensa